Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcutis Biotherapeutics (ARQT) Equity Ratio (2020 - 2025)

Arcutis Biotherapeutics (ARQT) has 6 years of Equity Ratio data on record, last reported at 0.39 in Q2 2025.

  • For Q2 2025, Equity Ratio changed N/A year-over-year to 0.39; the TTM value through Jun 2025 reached 0.39, changed N/A, while the annual FY2024 figure was 0.45, 73.85% up from the prior year.
  • Equity Ratio reached 0.39 in Q2 2025 per ARQT's latest filing, down from 0.41 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.94 in Q3 2021 and bottomed at 0.16 in Q3 2023.
  • Average Equity Ratio over 5 years is 0.46, with a median of 0.41 recorded in 2025.
  • Peak YoY movement for Equity Ratio: tumbled 70.03% in 2023, then soared 124.6% in 2024.
  • A 5-year view of Equity Ratio shows it stood at 0.73 in 2021, then crashed by 36.04% to 0.47 in 2022, then crashed by 44.32% to 0.26 in 2023, then soared by 73.85% to 0.45 in 2024, then dropped by 12.67% to 0.39 in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Ratio were 0.39 in Q2 2025, 0.41 in Q1 2025, and 0.45 in Q4 2024.